Orchard Therapeutics PLC – (NASDAQ:ORTX) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 1,220,234 shares, a growth of 103.7% from the February 15th total of 599,135 shares. Approximately 1.9% of the company’s stock are short sold. Based on an average daily trading volume, of 223,790 shares, the days-to-cover ratio is currently 5.5 days.

Several institutional investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Orchard Therapeutics during the 4th quarter worth about $629,000. FMR LLC acquired a new position in shares of Orchard Therapeutics during the 4th quarter worth about $321,012,000. Sofinnova Investments Inc. acquired a new position in shares of Orchard Therapeutics during the 4th quarter worth about $3,502,000. Millennium Management LLC acquired a new position in shares of Orchard Therapeutics during the 4th quarter worth about $4,554,000. Finally, RA Capital Management LLC acquired a new position in shares of Orchard Therapeutics during the 4th quarter worth about $76,227,000. Institutional investors own 57.82% of the company’s stock.

ORTX has been the topic of several analyst reports. Wedbush initiated coverage on shares of Orchard Therapeutics in a research report on Monday, November 26th. They set an “outperform” rating and a $25.00 price target on the stock. Goldman Sachs Group raised shares of Orchard Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $18.00 to $21.00 in a research report on Monday, December 17th. JPMorgan Chase & Co. initiated coverage on shares of Orchard Therapeutics in a research report on Monday, November 26th. They set an “overweight” rating and a $25.00 price target on the stock. ValuEngine cut shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Finally, Cowen initiated coverage on shares of Orchard Therapeutics in a research report on Monday, November 26th. They set an “outperform” rating and a $27.00 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $22.45.

Orchard Therapeutics stock opened at $16.25 on Friday. Orchard Therapeutics has a fifty-two week low of $8.65 and a fifty-two week high of $19.24.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2019/03/16/orchard-therapeutics-plc-ortx-short-interest-update.html.

Orchard Therapeutics Company Profile

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Featured Story: How to calculate compound interest

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.